FAQs
|
-
Isolation of ATCC® PCS-800-012 ™, Human Primary Bone Marrow CD34+ cells
CD34+ cells are isolated using positive immunomagnetic cell separation from the bone marrow. Date Updated: 8/27/2014
-
Purity of ATCC® PCS-800-012, Human Primary Bone Marrow CD34+ cells
ATCC CD34+ cells have been tested to have a purity of over 90% as measured by flow cytometry with a monoclonal CD34 antibody. Date Updated: 8/27/2014
-
Cryopreservative used with PCS-800-012
ATCC CD34+ cells are cryopreserved in CryoStor® CS10 Freeze Medium from BioLife Solutions. Date Updated: 8/27/2014
-
Long term culture of ATCC® PCS-800-012
CD34+ cells have a limited lifespan in culture and should only be thawed immediately prior to their intended use. ATCC does not recommend maintaining CD34+ cells in culture in the absence of appl... Date Updated: 8/27/2014
-
Post-thaw yield and viability of ATCC® PCS-800-012 ™ Human Primary Bone Marrow CD34+ cells
We recommend the following thawing procedure: Date Updated: 1/12/2017
-
CD34 positive primary cells from non-normal donors
No, at this time ATCC does not offer CD34+ cells from non-normal donors. The ATCC® PCS-800-012 ™, Human Primary Bone Marrow CD34+ cells are from normal donor sources. Date Updated: 8/27/2014
|
References
|
Mahalingaiah PK, et al. An In Vitro Model of Hematotoxicity: Differentiation of Bone Marrow-Derived Stem/Progenitor Cells into Hematopoietic Lineages and Evaluation of Lineage-Specific Hematotoxicity. Current Protocols Toxicol 76(1), 2018. DOI: 10.1002/cptx.45
Li Z, et al. Mesenchymal stem cells promote endothelial progenitor cell migration, vascularization, and bone repair in tissue-engineered constructs via activating CXCR2-Src-PKL/Vav2-Rac1. FASEB 32(4):2197-2211, 2018. PubMed: 29229683
Nicolae CM, et al. NFkB regulates p21 expression and controls DNA damage-induced leukemic differentiation. Oncogene 2018. PubMed: 29622796
Yivgi-Ohana N, Halavee U. Mammalian cells enriched with functional mitochondria. Patent Application Publication Pub. No.: US 2018/0030413 A1, 2018.
Wang B, Zeiner G. Smart CAR Devices and DE CAR Polypeptides for Treating Disease and Methods for Enhancing Immune Responses. Patent Application Publication Pub. No.: US 2017/0157176 A1, 2017.
|